F-15,599: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Dr |
Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5) (Maxim Masiutin - 17956 |
||
(56 intermediate revisions by 34 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
⚫ | |||
| Watchedfields = changed |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_status = |
| legal_status = Investigational |
||
| routes_of_administration = Oral |
| routes_of_administration = Oral |
||
Line 14: | Line 17: | ||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = |
||
| excretion = |
| excretion = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| |
| IUPHAR_ligand = 3924 |
||
| CAS_number_Ref = {{cascite|correct|CAS}} |
|||
| ATC_prefix = none |
|||
| CAS_number=635323-95-4 |
|||
| ATC_suffix = |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
⚫ | |||
| UNII = 83481Y1YCX |
|||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
| ChemSpiderID = 9916065 |
|||
⚫ | |||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=19 | H=22 | Cl=1 | F=2 | N=4 | O=1 |
| C=19 | H=22 | Cl=1 | F=2 | N=4 | O=1 |
||
| molecular_weight = 395.854 g/mol |
|||
| smiles = Cc3cnc(nc3)CNCC(F)(CC2)CCN2C(=O)c(cc1Cl)ccc1F |
| smiles = Cc3cnc(nc3)CNCC(F)(CC2)CCN2C(=O)c(cc1Cl)ccc1F |
||
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|||
| StdInChI = 1S/C19H21ClF2N4O/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14/h2-3,8-10,23H,4-7,11-12H2,1H3 |
|||
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|||
| StdInChIKey = WAAXKNFGOFTGLP-UHFFFAOYSA-N |
|||
}} |
}} |
||
'''F-15,599''' is a |
'''F-15,599''', also known as '''NLX-101''', is a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[full agonist]].<ref name="pmid17803293">{{cite journal |vauthors=Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B |title=High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity |journal=Journal of Medicinal Chemistry |volume=50 |issue=20 |pages=5024–33 | date=October 2007 |pmid=17803293 |doi=10.1021/jm070714l}}</ref><ref name="pmid19154445">{{cite journal |vauthors=Newman-Tancredi A, Martel JC, Assié MB |title=Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist |journal=British Journal of Pharmacology |volume=156 |issue=2 |pages=338–53 | date=January 2009 |pmid=19154445 |pmc=2697830 |doi=10.1111/j.1476-5381.2008.00001.x|display-authors=etal}}</ref> It displays [[functional selectivity]] (also known as "biased agonism") by strongly activating 5-HT<sub>1A</sub> receptors in the [[postsynaptic]] [[prefrontal cortex]] while having little effect on [[somatodendritic]] [[autoreceptor]]s in the [[raphe nucleus]].<ref name=pmid17803293 /><ref name=pmid19154445 /> As a result, it has been touted as a preferential postsynaptic 5-HT<sub>1A</sub> receptor agonist and has been investigated as a novel potential [[antidepressant]].<ref name= pmid17803293/><ref name=pmid19154445 /><ref>{{cite journal |vauthors=Assié MB, Bardin L, Auclair AL |title=F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity |journal=The International Journal of Neuropsychopharmacology |volume=13 |issue=10 |pages=1285–98 | date=November 2010 |pmid=20059805 |doi=10.1017/S1461145709991222|display-authors=etal|doi-access=free }}</ref> |
||
In cognitive tests in rodent, F-15,599 attenuates memory deficits elicited by the NMDA receptor antagonist PCP, suggesting that it may improve cognitive function in disorders such as schizophrenia.<ref>{{cite journal |vauthors=Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A |title=F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists |journal=European Neuropsychopharmacology |volume=20 |issue=9 |pages=641–54 | date=September 2010 |pmid=20488670 |doi=10.1016/j.euroneuro.2010.04.005|s2cid=22222213 }}</ref> |
|||
⚫ | |||
A subsequent study showed that F-15,599 reduces breathing irregularity and apneas observed in mice with mutations of the MeCP2 gene.<ref>{{cite journal |vauthors=Levitt ES, Hunnicutt BJ, Knopp SJ, Williams JT, Bissonnette JM |title=A selective 5-HT1a receptor agonist improves respiration in a mouse model of Rett syndrome |journal=Journal of Applied Physiology |volume=115 |issue=11 |pages=1626–33 | date=December 2013 |pmid=24092697 |doi=10.1152/japplphysiol.00889.2013 |pmc=3882741}}</ref> Dysruption of MeCP2 gene expression underlies [[Rett syndrome]], a debilitating neurodevelopmental [[orphan disease]]. |
|||
F-15,599 was discovered and initially developed by [[Pierre Fabre Group|Pierre Fabre Médicament]], a French pharmaceuticals company. In September 2013, F-15,599 was out-licensed to [[Neurolixis]], a California-based biotechnology company. Neurolixis announced that it intends to re-purpose F-15,599 for the treatment of [[Rett syndrome]].<ref>http://neurolixis.com/images/stories/nlx_pf_license_23sept13.pdf{{full citation needed|date=June 2015}}</ref> and obtained [[orphan drug]] designation from the United States [[Food and Drug Administration]] (FDA)<ref>{{Cite web|url=http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=410613|title=Enforcement Reports|access-date=2014-03-03|archive-date=2015-02-24|archive-url=https://web.archive.org/web/20150224233953/http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=410613|url-status=dead}}</ref> and from the European Commission for this indication.<ref>{{Cite web|url=http://ec.europa.eu/health/documents/community-register/html/o1242.htm|title = Public Health - European Commission}}</ref> |
|||
Researchers at the [[University of Bristol]] are investigating the activity of F-15599 in animal models of Rett Syndrome, with support from the International Rett Syndrome Foundation.<ref>{{Cite web|url=http://www.bristol.ac.uk/news/2014/april/rett-syndrome-research.html|title = April: Rett syndrome research | News and features | University of Bristol}}</ref> In June 2015, the Rett Syndrome Research Trust awarded a grant to Neurolixis to advance F-15599 to clinical development.<ref>{{Cite web|url=https://rettsyndrome.wordpress.com/2015/06/24/rsrt-awards-530000-to-neurolixis-for-clinical-development-of-nlx-101/|title = RSRT Awards $530,000 to Neurolixis for Clinical Development of NLX-101|date = 24 June 2015}}</ref> |
|||
⚫ | |||
* [[Befiradol]] (F-13,640) |
* [[Befiradol]] (F-13,640) |
||
* [[Eptapirone]] (F-11,440) |
* [[Eptapirone]] (F-11,440) |
||
== |
==References== |
||
{{Reflist}} |
{{Reflist|2}} |
||
==External links== |
|||
* [http://adisinsight.springer.com/drugs/800041224 F-15599 - AdisInsight] |
|||
{{Antidepressants}} |
{{Antidepressants}} |
||
Line 45: | Line 65: | ||
[[Category:Piperidines]] |
[[Category:Piperidines]] |
||
[[Category:Pyrimidines]] |
[[Category:Pyrimidines]] |
||
[[Category: |
[[Category:Benzamides]] |
||
[[Category: |
[[Category:Chloroarenes]] |
||
[[Category:Organofluorides]] |
[[Category:Organofluorides]] |
||
[[Category:5-HT1A agonists]] |
|||
[[Category:Fluoroarenes]] |
|||
{{nervous-system-drug-stub}} |